Journal Home
Search for

Volume 60, Issue 5, Pages 808-813 (May 2009)


View previous. 21 of 53 View next.

Minichromosome maintenance proteins are useful adjuncts to differentiate between benign and malignant melanocytic skin lesions

Thilo Gambichler, MDCorresponding Author Informationemail address, Marina Shtern, MD, Sebastian Rotterdam, MD, Falk G. Bechara, MD, Markus Stücker, MD, Peter Altmeyer, MD, Alexander Kreuter, MD

Background

Markers identifying premalignant and malignant melanocytic skin lesions are needed.

Objective

We aimed to investigate the protein expression of minichromosome maintenance (MCM) proteins in melanocytic skin lesions with different malignant potential.

Methods

Paraffin-embedded sections of benign melanocytic nevi (BN, n = 37), dysplastic nevi (DN, n = 25), and primary superficial spreading (SSM, n = 58) were assessed. Immunohistochemistry was performed for Ki-67, MCM3, MCM4, and MCM7 antibodies.

Results

Ki-67 expression of SSM was significantly increased when compared to DN (P = .0001) and BN (P = .0015). Compared to BN and DN, expression of MCM3 was significantly increased in SSM (P < .0001 and P = .019, respectively). MCM3 expression of DN was significantly increased as compared to BN (P = .0067). There was a significant correlation between MCM3 expression and Breslow tumor thickness (r = 0.44, P = .019). In SSM, MCM4 expression was significantly increased when compared with DN (P < .0001) and BN (P = .0033). MCM4 immunoreactivity was significantly higher in DN than in BN (P = .016). Immunohistology of MCM7 did not reveal significant differences between the groups investigated (P = .48). However, immunoreactivity of MCM7 significantly correlated with Breslow tumor thickness and Clark level (r = 0.39, P = .023; r = 0.44, P = .010, respectively).

Limitations

Limitations of our study include the absence of survival data, mRNA results, and functional studies.

Conclusions

MCM3 as well as MCM4 are differentially expressed in BN, DN, and SSM. Hence, immunolabeling of MCM3 and MCM4 proteins appears to be a promising additive tool for distinguishing benign from malignant melanocytic skin lesions.

Department of Dermatology and Allergology, Ruhr-University Bochum, Bochum, Germany

Corresponding Author InformationReprint requests: Thilo Gambichler, MD, Department of Dermatology and Allergology, Ruhr-University Bochum, Gudrunstrasse 56, D-44791 Bochum, Germany.

 This work was funded by Forschungsförderung Ruhr-Universität Bochum Medizinischen Fakultät (FoRUM, Project No. F615-2008).

 Conflicts of interest: None declared.

PII: S0190-9622(09)00125-X

doi:10.1016/j.jaad.2009.01.028


View previous. 21 of 53 View next.